Transforming Growth Factor-Beta in Cancer Therapy, Volume II

Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge about the current state ofour understanding oftransforming growth factor-B (TGF-B) in cancer treatment and therapy. Unlike several more traditional positive polypeptide growth factors that stim ulate cellular proliferation, the prototypical TGF-B is now known to inhibit the growth of most normal cell types, including those of epithelial and mesenchymal origin. However, there are examplesofcell types that can be stimulated by TGF-B under certain conditions. TGF-B also induces the accumulation of matrix molecules by stimulating their synthesis as well as inhibiting their degradation. Moreover, TGF-B induces apoptosis of certain cell types, thereby restricting their proliferation. OveractivityofTGF-~ has been linked to several diseases. For instance, the effect ofTGF-~ on matrix accumulation contributes to fibrotic conditions, like glomerulonephritis, lung fibrosis and liver cirrhosis (1). TGF-~ has a very complicated role in cancer that is only beginning to be understood.

Details the role of TGF- ß in cancer treatment and therapy, including its role in development and progression of several different cancers Conveniently divided into three easy-to-follow parts Companion volume details the role of TGF- ß on basic and clinical biology

Klappentext

Transforming Growth Factor-ß in Cancer Therapy, Volumes 1 and 2, provides a compendium of findings about the role of transforming growth factor-ß (TGF-ß) in cancer treatment and therapy. The second volume, Cancer Treatment and Therapy, is divided into three parts. Part I examines transforming growth factor-ß in developing and advanced cancers. Part II details transforming growth factor-ß in cancer treatment and therapy. Part III includes an investigation into the development of inhibitors of transforming growth factor-ß signaling for therapy.

This volume's companion, Basic and Clinical Biology, examines transforming growth factor-ß signaling in normal physiology, cancer pathobiology, normal and tumor biology, and inflammation and fibrosis. Together, Transforming Growth Factor-ß in Cancer Therapy, Volumes 1 and 2, provide researchers and clinicians with a comprehensive and cutting-edge reference for the findings about the role of transforming growth factor-ß in biology and cancer treatment.

Inhalt
Transforming Growth Factor-? In Developing and Advanced Cancers.- Transforming Growth Factor-? Signaling in Pancreas Development and Pancreatic Disease.- Role of Transforming Growth Factor-? in the Pathogenesis of Human Head and Neck Squamous Cell Carcinoma.- TGF-?, Smads and Cervical Cancer.- TGF-? Signaling and Biglycan in Pancreatic Cancer.- TGF-? Signaling in Endometrial Cancer.- TGF-? Ligands, TGF-? Receptors, and Lung Cancer.- Role of TGF-? in Osteolytic Bone Metastases.- Hormonal Regulation of Transforming Growth Factor-? in Breast Cancer.- TGF-? and Progression of Esophageal Cancer.- TGF-? and HER2/ErbB2 and Breast Cancer Progression.- TGF-? Dependent T-Cell Regulation in Colitis and Colon Cancer.- Role of Transforming Growth Factor-? in the Kidney Physiology and Pathology.- Perturbations of TGF-? Signaling in Leukocytes as Drivers of Leukemogenesis and Epithelial Tumorigenesis.- Transforming Growth Factor-? in Brain Functions and Dysfunctions.- Inhibition of TGF-? Signaling in Multiple Myeloma and Its Bone Marrow Microenvironment.- Key Roles of TGF-? and Smad3 in Prostate Cancer.- Smad Signaling in Leukemic Growth and Differentiation: Crosstalk Between Smad and Multiple Pathways Through Activation of the TGF-? Type I Receptor.- Transforming Growth Factor-? in Cancer Treatment and Therapy.- High-Throughput Screening of Protein Interaction Networks in the TGF? Interactome: Understanding the Signaling Mechanisms Driving Tumor Progression.- Tumor Suppressor and Pro-progression Roles for TGF-? in Breast Cancer.- Tumor Suppressors p53 and TGF? Converge to Regulate the Alpha-Fetoprotein Oncodevelopmental Tumor Marker.- TGF?: Roles in DNA Damage Responses.- The Rationale for and Effects of Targeting TGF-? for Glioma Therapy.- TumorSuppressor Functions of TGF?1 in T Cells.- Therapeutic Effects of Adenovirus-Mediated Gene Transfer of TGF-? Signal Antagonists on Undesirable Epithelial-Mesenchymal Transition and Neovascularization.- Role of TGF-? in Tumor Protection and Antitumor Immunity.- Regulation of Angiogenesis and Tumor Growth by Thrombospondin-1.- Cancer-Associated Fibroblasts and the Role of TGF-?.- Adoptive Transfer of Tumor Reactive TGF-? Insensitive CD8+ T-cells for Cancer Therapy.- DNA Methylation and Histone Deacetylation Inhibitors as Potential Therapeutic Agents for the Reconstitution of TGF-? Signaling in Breast Cancer.- Reactive Stroma and Evolution of Tumors: Integration of Transforming Growth Factor-?, Connective Tissue Growth Factor, and Fibroblast Growth Factor-2 Activities.- TGF-? Signaling and Vascular Morphogenesis.- Aberrant Transforming Growth Factor-? Signaling in Human Pancreatic Cancer: Translational Implications.- TGF-? and Stromal Influences Over Local Tumor Invasion.- TGF-? at the Crossroads Between Inflammation, Suppression and Cancer.- Development of Inhibitors of Transforming Growth Factor-? Signaling for Therapy.- Transforming Growth Factor-? (TGF-?) Signaling Inhibitors in Cancer Therapy.- Targeting TGF-? as a Strategy to Ameliorate Intestinal Side Effects of Radiation Therapy.- Targeting Transforming Growth Factor-? in Metastasis: In Vitro and In Vivo Mechanisms.- Targeted Downregulation of TGF-?2 with AP 12009 in Tumor Therapy.- Modulating TGF-? Receptor Signaling: A Novel Approach of Cancer Therapy.- Engineering TGF-? Traps: Artificially Dimerized Receptor Ectodomains as High-affinity Blockers of TGF-? Action.- The Use of Virtual Screening in ALK5 Kinase Inhibitor Discovery and Validation of Orally Active ALK5 Kinase Inhibitors inOncology.- Soluble Type II Transforming Growth Factor-? Receptor Inhibits Tumorigenesis by Augmenting Host Antitumor Immunity.- Reversal of EMT by Small-Molecule Inhibitors of TGF-? Type I and II Receptors: Implications for Carcinoma Treatment.- Soluble TGF-? Type III Receptor Suppresses Malignant Progression of Human Cancer Cells.- Targeting Smad-Dependent TGF-? Signaling with Peptide Aptamers.- Rationale for Anti-TGF-? Antibody Therapy in Oncology.